Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

About Momenta Pharmaceuticals

Momenta Pharmaceuticals logoMomenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MNTA
  • CUSIP: 60877T10
Key Metrics:
  • Previous Close: $19.00
  • 50 Day Moving Average: $16.71
  • 200 Day Moving Average: $13.64
  • 52-Week Range: $68,957,000.00 - $7.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -37.25
  • P/E Growth: 0.00
  • Market Cap: $1.31B
  • Outstanding Shares: 68,957,000
  • Beta: 1.81
Profitability:
  • Net Margins: -93.75%
  • Return on Equity: -26.55%
  • Return on Assets: -21.69%
Debt:
  • Current Ratio: 7.47%
  • Quick Ratio: 7.47%
Additional Links:
Companies Related to Momenta Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Momenta Pharmaceuticals (NASDAQ:MNTA) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $16.78 (11.70% downside)

Analysts' Ratings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Show:
DateFirmActionRatingPrice TargetDetails
2/6/2017AegisReiterated RatingHold$17.00View Rating Details
1/31/2017Leerink SwannSet Price TargetBuy$20.00View Rating Details
2/1/2017Maxim GroupReiterated RatingSell$6.00View Rating Details
1/31/2017Barclays PLCBoost Price TargetOverweight$19.00 -> $20.00View Rating Details
1/8/2017Stifel NicolausReiterated RatingBuy$20.00View Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingBuy$18.00View Rating Details
8/7/2016Cowen and CompanyReiterated RatingHoldView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$19.00View Rating Details
6/6/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$14.00View Rating Details
8/24/2015Sanford C. BernsteinReiterated RatingBuyView Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017Q416($0.24)$29.56 millionN/AView Earnings Details
11/2/2016Q316($0.29)($0.26)$25.68 million$299.14 millionViewN/AView Earnings Details
8/4/2016Q216($0.32)($0.31)$23.55 million$26.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.35)$28.12 million$19.90 millionViewN/AView Earnings Details
2/18/2016Q415($0.04)($0.43)$30.42 million$22.40 millionViewListenView Earnings Details
11/4/2015Q315($0.19)($0.44)$31.76 million$13.80 millionViewListenView Earnings Details
8/4/2015Q215($0.39)($0.04)$23.59 million$44.90 millionViewListenView Earnings Details
5/1/2015Q115($0.48)($0.40)$11.70 million$8.60 millionViewN/AView Earnings Details
2/17/2015Q414($0.26)($0.31)$23.80 million$21.18 millionViewListenView Earnings Details
11/5/2014Q314($0.43)($0.56)$13.00 million$9.34 millionViewListenView Earnings Details
7/31/2014Q214($0.46)($0.51)$11.22 million$11.00 millionViewListenView Earnings Details
5/6/2014Q1($0.55)($0.53)$8.41 million$10.79 millionViewListenView Earnings Details
2/10/2014Q4($0.45)($0.59)$8.50 million$12.80 millionViewListenView Earnings Details
11/5/2013Q313($0.48)($0.50)$8.60 million$10.80 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.45)($0.57)$8.85 million$4.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.44)($0.48)$10.28 million$7.60 millionViewN/AView Earnings Details
2/15/2013Q4 2012($0.41)($0.35)$10.41 million$12.70 millionViewN/AView Earnings Details
11/7/2012Q312($0.27)($0.51)$16.48 million$5.10 millionViewN/AView Earnings Details
8/2/2012($0.17)($0.20)ViewN/AView Earnings Details
5/3/2012$0.02($0.10)ViewN/AView Earnings Details
2/9/2012$0.13($0.02)ViewN/AView Earnings Details
11/7/2011$1.28$1.18ViewN/AView Earnings Details
8/4/2011$1.21$1.26ViewN/AView Earnings Details
5/5/2011$0.95$1.13ViewN/AView Earnings Details
2/10/2011$0.81$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)
Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-0.51 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.36)($0.36)($0.36)
Q3 20161($0.34)($0.34)($0.34)
Q4 20161($0.29)($0.29)($0.29)
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171$0.06$0.06$0.06
Q4 20171($0.01)($0.01)($0.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Momenta Pharmaceuticals (NASDAQ:MNTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 84.44%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Richard P SheaCFOSell9,799$15.00$146,985.00View SEC Filing  
12/9/2016Richard P SheaCFOSell1,451$15.00$21,765.00View SEC Filing  
11/22/2016Bruce LeicherSVPSell1,030$13.66$14,069.80View SEC Filing  
11/22/2016Craig A. WheelerPresidentSell5,880$13.68$80,438.40View SEC Filing  
11/22/2016James M RoachVPSell1,091$13.67$14,913.97View SEC Filing  
11/22/2016Richard P SheaCFOSell971$13.67$13,273.57View SEC Filing  
8/22/2016Bruce LeicherSVPSell1,030$12.05$12,411.50View SEC Filing  
8/22/2016Craig A. WheelerPresidentSell5,880$12.02$70,677.60View SEC Filing  
8/22/2016James M RoachVPSell1,091$12.05$13,146.55View SEC Filing  
8/22/2016Richard P SheaCFOSell972$12.05$11,712.60View SEC Filing  
5/20/2016Bruce LeicherSVPSell1,000$10.40$10,400.00View SEC Filing  
5/20/2016Craig A WheelerPresidentSell5,880$10.18$59,858.40View SEC Filing  
5/20/2016Ganesh Venkataraman KaundinyaVPSell1,050$10.18$10,689.00View SEC Filing  
5/20/2016Richard P SheaCFOSell973$10.18$9,905.14View SEC Filing  
5/19/2016John E BishopVPSell784$10.20$7,996.80View SEC Filing  
4/19/2016John E BishopVPSell2,843$9.57$27,207.51View SEC Filing  
2/23/2016John E BishopVPSell329$9.70$3,191.30View SEC Filing  
2/22/2016Bruce LeicherSVPSell227$9.65$2,190.55View SEC Filing  
2/22/2016Craig A WheelerPresidentSell1,688$9.95$16,795.60View SEC Filing  
2/22/2016John E BishopVPSell2,848$9.66$27,511.68View SEC Filing  
2/19/2016Bruce LeicherSVPSell2,000$9.64$19,280.00View SEC Filing  
2/19/2016Craig A WheelerPresidentSell9,844$9.37$92,238.28View SEC Filing  
2/19/2016John E. BishopVPSell357$10.28$3,669.96View SEC Filing  
2/19/2016Richard P SheaCFOSell1,823$9.64$17,573.72View SEC Filing  
2/18/2016Bruce LeicherSVPSell337$10.49$3,535.13View SEC Filing  
2/18/2016James M RoachVPSell272$10.49$2,853.28View SEC Filing  
2/18/2016Richard P SheaCFOSell183$10.49$1,919.67View SEC Filing  
2/17/2016Craig A WheelerPresidentSell1,688$11.30$19,074.40View SEC Filing  
12/11/2015Michael FrankenInsiderSell520$15.84$8,236.80View SEC Filing  
11/20/2015Craig A WheelerPresidentSell1,766$17.86$31,540.76View SEC Filing  
11/19/2015Craig A WheelerPresidentSell2,061$18.05$37,201.05View SEC Filing  
11/17/2015Craig A WheelerPresidentSell1,766$17.70$31,258.20View SEC Filing  
11/5/2015Craig A. WheelerPresidentSell51,667$18.00$930,006.00View SEC Filing  
8/20/2015Craig A WheelerPresidentSell1,766$22.28$39,346.48View SEC Filing  
8/19/2015Craig A WheelerPresidentSell2,061$22.02$45,383.22View SEC Filing  
8/19/2015James M. RoachVPSell7,011$22.09$154,872.99View SEC Filing  
8/18/2015James M RoachVPSell6,812$21.80$148,501.60View SEC Filing  
8/17/2015Craig A WheelerPresidentSell1,766$21.77$38,445.82View SEC Filing  
7/15/2015Elizabeth StonerDirectorSell4,570$22.35$102,139.50View SEC Filing  
6/19/2015John E BishopVPSell21,274$25.50$542,487.00View SEC Filing  
6/18/2015Bruce LeicherSVPSell20,000$23.00$460,000.00View SEC Filing  
6/18/2015Craig A WheelerPresidentSell155,000$24.20$3,751,000.00View SEC Filing  
6/18/2015John E BishopVPSell36,313$23.58$856,260.54View SEC Filing  
6/4/2015Craig A WheelerPresidentSell103,333$22.00$2,273,326.00View SEC Filing  
6/1/2015Bruce LeicherSVPSell40,000$21.00$840,000.00View SEC Filing  
6/1/2015James M RoachVPSell25,000$21.70$542,500.00View SEC Filing  
5/20/2015Craig A WheelerPresidentSell1,766$19.68$34,754.88View SEC Filing  
5/19/2015Craig A WheelerPresidentSell2,061$19.67$40,539.87View SEC Filing  
4/23/2015Craig A WheelerPresidentSell51,667$20.00$1,033,340.00View SEC Filing  
4/23/2015Ganesh Venkataraman KaundinyaVPSell34,000$19.95$678,300.00View SEC Filing  
4/20/2015Craig A WheelerPresidentSell6,269$18.75$117,543.75View SEC Filing  
4/17/2015Bruce LeicherSVPSell52,910$19.52$1,032,803.20View SEC Filing  
4/16/2015James M RoachVPSell50,000$18.70$935,000.00View SEC Filing  
3/16/2015Richard P SheaCFOSell23,093$15.10$348,704.30View SEC Filing  
3/5/2015Richard P SheaCFOSell23,364$14.90$348,123.60View SEC Filing  
2/24/2015Craig A WheelerPresidentSell2,110$13.52$28,527.20View SEC Filing  
2/20/2015Bruce LeicherSVPSell1,891$12.97$24,526.27View SEC Filing  
2/20/2015Craig A WheelerPresidentSell9,563$13.49$129,004.87View SEC Filing  
2/20/2015John E BishopVPSell1,768$12.97$22,930.96View SEC Filing  
2/20/2015Richard P SheaCFOSell1,812$12.97$23,501.64View SEC Filing  
2/18/2015Craig A WheelerPresidentSell1,688$11.91$20,104.08View SEC Filing  
12/15/2014Bennett M ShapiroDirectorSell5,800$12.19$70,702.00View SEC Filing  
12/11/2014Michael FrankenInsiderSell2,047$12.29$25,157.63View SEC Filing  
12/1/2014Bennett M ShapiroDirectorSell9,903$12.00$118,836.00View SEC Filing  
11/28/2014Bennett M ShapiroDirectorSell1,897$12.00$22,764.00View SEC Filing  
11/25/2014Craig A WheelerPresidentSell2,210$11.59$25,613.90View SEC Filing  
11/20/2014Craig A WheelerPresidentSell1,768$11.10$19,624.80View SEC Filing  
11/17/2014Craig A WheelerPresidentSell1,768$10.58$18,705.44View SEC Filing  
10/3/2014Bennett M ShapiroDirectorSell3,723$12.00$44,676.00View SEC Filing  
9/12/2014Peter Barton HuttDirectorSell3,640$11.42$41,568.80View SEC Filing  
8/25/2014Craig A WheelerPresidentSell2,209$11.45$25,293.05View SEC Filing  
8/20/2014Craig A WheelerPresidentSell1,768$11.54$20,402.72View SEC Filing  
8/15/2014Bennett M ShapiroDirectorSell3,722$12.00$44,664.00View SEC Filing  
8/15/2014Craig A WheelerPresidentSell1,768$11.75$20,774.00View SEC Filing  
8/13/2014Bennett M ShapiroDirectorSell3,721$12.00$44,652.00View SEC Filing  
5/23/2014Craig A WheelerPresidentSell2,110$12.06$25,446.60View SEC Filing  
5/20/2014Craig WheelerPresidentSell1,688$12.08$20,391.04View SEC Filing  
5/15/2014Craig WheelerPresidentSell1,687$11.09$18,708.83View SEC Filing  
2/25/2014Craig WheelerPresidentSell2,109$17.47$36,844.23View SEC Filing  
2/24/2014John BishopVPSell1,038$17.67$18,341.46View SEC Filing  
2/19/2014Craig WheelerPresidentSell3,797$17.90$67,966.30View SEC Filing  
2/12/2014Ganesh Venkataraman KaundinyaVPSell33,000$17.96$592,680.00View SEC Filing  
1/9/2014John BishopVPSell27,159$19.50$529,600.50View SEC Filing  
11/25/2013Bruce LeicherSVPSell13,492$18.00$242,856.00View SEC Filing  
11/25/2013Craig WheelerPresidentSell2,215$17.77$39,360.55View SEC Filing  
11/25/2013Ganesh Venkataraman KaundinyaVPSell33,211$18.02$598,462.22View SEC Filing  
11/19/2013Craig WheelerPresidentSell2,215$17.17$38,031.55View SEC Filing  
11/15/2013Craig WheelerPresidentSell1,772$16.88$29,911.36View SEC Filing  
10/11/2013John BishopVPSell5,247$15.46$81,118.62View SEC Filing  
8/23/2013Craig WheelerPresidentSell2,109$14.90$31,424.10View SEC Filing  
8/20/2013Craig WheelerPresidentSell2,109$14.47$30,517.23View SEC Filing  
8/15/2013Craig WheelerPresidentSell1,688$15.43$26,045.84View SEC Filing  
7/26/2013Richard P SheaCFOSell30,000$16.61$498,300.00View SEC Filing  
6/27/2013Richard P SheaCFOSell10,522$14.61$153,726.42View SEC Filing  
6/19/2013Richard P SheaCFOSell21,550$14.61$314,845.50View SEC Filing  
5/23/2013Craig A WheelerPresidentSell2,109$13.03$27,480.27View SEC Filing  
5/21/2013Craig A WheelerPresidentSell2,109$12.83$27,058.47View SEC Filing  
5/15/2013Craig A WheelerPresidentSell1,687$13.33$22,487.71View SEC Filing  
3/5/2013Elizabeth StonerDirectorSell2,040$14.00$28,560.00View SEC Filing  
2/15/2013Bruce LeicherSVPSell1,040$12.26$12,750.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateHeadline
globenewswire.com logoMomenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill ... - GlobeNewswire (press release) (NASDAQ:MNTA)
globenewswire.com - February 19 at 9:53 AM
finance.yahoo.com logoMomenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results ... - Yahoo Finance (NASDAQ:MNTA)
finance.yahoo.com - February 18 at 5:48 PM
marketwatch.com logoMomenta Pharma shares halted as drug application hits speed bump - MarketWatch (NASDAQ:MNTA)
www.marketwatch.com - February 18 at 5:48 PM
streetinsider.com logoMomenta Phama (MNTA) Says Glatopa Fill/Finish Manufacturing Partner Received an FDA Warning Letter (NASDAQ:MNTA)
www.streetinsider.com - February 18 at 12:26 PM
us.rd.yahoo.com logoMomenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer (NASDAQ:MNTA)
us.rd.yahoo.com - February 18 at 12:26 PM
marketwatch.com logoMomenta Pharma shares halted as drug application hits speed bump (NASDAQ:MNTA)
www.marketwatch.com - February 18 at 12:25 PM
feeds.benzinga.com logoMomenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast (NASDAQ:MNTA)
feeds.benzinga.com - February 17 at 6:51 PM
streetinsider.com logoMomenta Phama (MNTA) Receives HSR Clearance for Collaboration and License Agreement with CSL (NASDAQ:MNTA)
www.streetinsider.com - February 17 at 4:01 PM
finance.yahoo.com logoMomenta Pharmaceuticals Announces HSR Clearance for Collaboration and License Agreement with CSL (NASDAQ:MNTA)
finance.yahoo.com - February 17 at 4:01 PM
News IconTrading Sheet: Reviewing the Levels for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Davidson Register (NASDAQ:MNTA)
davidsonregister.com - February 14 at 8:09 PM
News IconStock Update: Focusing on Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Midway Monitor (NASDAQ:MNTA)
midwaymonitor.com - February 14 at 8:09 PM
us.rd.yahoo.com logoTeva Pharm Q4 profit, revenue beat expectations (NASDAQ:MNTA)
us.rd.yahoo.com - February 13 at 7:45 PM
sg.finance.yahoo.com logoTeva seeks CEO with pharma background to lead recovery efforts (NASDAQ:MNTA)
sg.finance.yahoo.com - February 13 at 7:45 PM
finance.yahoo.com logoForget Gilead, Buy These 5 Biotech Stocks Instead (NASDAQ:MNTA)
finance.yahoo.com - February 13 at 10:18 AM
finance.yahoo.com logoCan The Uptrend Continue for Momenta Pharmaceuticals (MNTA)? (NASDAQ:MNTA)
finance.yahoo.com - February 10 at 5:40 AM
News IconShares in Review: Momenta Pharmaceuticals Inc. (MNTA) - Piedmont Register (NASDAQ:MNTA)
piedmontregister.com - February 8 at 5:57 AM
feeds.benzinga.com logoMomenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast (NASDAQ:MNTA)
feeds.benzinga.com - February 7 at 9:19 AM
News IconMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Analytical Analysis - The Newburgh Press (NASDAQ:MNTA)
newburghpress.com - February 3 at 7:21 PM
News IconMomenta Pharmaceuticals, Inc. 25.8% Potential Upside Now Implied by Barclays (NASDAQ:MNTA)
viveremilano.biz - February 3 at 12:30 AM
istreetwire.com logoStocks Buzz: Blackstone Mortgage Trust, Inc. (BXMT), Momenta Pharmaceuticals, Inc. (MNTA), Palatin Technologies ... - iStreetWire (NASDAQ:MNTA)
istreetwire.com - February 2 at 7:28 PM
News IconNext Weeks Broker Price Targets For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) (NASDAQ:MNTA)
cote-ivoire.com - February 2 at 12:31 AM
News IconWhat are Analysts report about: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) (NASDAQ:MNTA)
emfizz.com - February 2 at 12:31 AM
rttnews.com logoMomenta Pharmaceuticals Inc. (MNTA) Surged To A New High On Patent Ruling (NASDAQ:MNTA)
www.rttnews.com - February 2 at 12:31 AM
News IconMomenta Pharmaceuticals (NASDAQ:MNTA) Receives 'Overweight' Rating From Brokers At Barclays Capital (NASDAQ:MNTA)
hoyentv.com - February 2 at 12:31 AM
News IconEarnings Forecast Research on Momenta Pharmaceuticals, Inc. (MNTA) (NASDAQ:MNTA)
onemma.net - February 2 at 12:31 AM
us.rd.yahoo.com logoMomenta Pharmaceuticals to Webcast Presentation at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:MNTA)
us.rd.yahoo.com - February 2 at 12:31 AM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)? - Wall Street Beacon (NASDAQ:MNTA)
wsbeacon.com - February 1 at 7:30 PM
finance.yahoo.com logoMomenta Pharmaceuticals to Webcast Presentation at the Leerink ... - Yahoo Finance (NASDAQ:MNTA)
finance.yahoo.com - February 1 at 7:30 PM
finance.yahoo.com logoMomenta Says District of Delaware Invalidates Teva's MS Drug (NASDAQ:MNTA)
finance.yahoo.com - February 1 at 7:30 PM
News IconMomenta Announces District Court Decision To Invalidate Teva Patents In COPAXONE (Glatiramer Acetate Injection) 40 Mg/Ml Litigation (NASDAQ:MNTA)
www.biospace.com - February 1 at 12:31 AM
investingnews.com logoMomenta Pharmaceuticals Announces District Court Decision to Invalidate Teva Patents in COPAXONE® Litigation (NASDAQ:MNTA)
investingnews.com - February 1 at 12:31 AM
streetinsider.com logoMomenta Phama (MNTA) 'Pleased' with District Court Decision to Invalidate Teva's (TEVA) Patents in COPAXONE (NASDAQ:MNTA)
www.streetinsider.com - February 1 at 12:31 AM
us.rd.yahoo.com logoMomenta Pharmaceuticals Announces District Court Decision to Invalidate Teva Pharmaceuticals Patents in COPAXONE® (glatiramer acetate injection) 40 mg/mL Litigation (NASDAQ:MNTA)
us.rd.yahoo.com - February 1 at 12:31 AM
us.rd.yahoo.com logo8:04 am Momenta Pharma announces a US District Court ruling against Teva (TEVA (NASDAQ:MNTA)
us.rd.yahoo.com - February 1 at 12:31 AM
thestreet.com logoPremarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics (NASDAQ:MNTA)
us.rd.yahoo.com - February 1 at 12:31 AM
thestreet.com logoMylan's Shares Rise Despite FTC Investigation (NASDAQ:MNTA)
us.rd.yahoo.com - February 1 at 12:30 AM
fool.com logoInstant Analysis: Is Teva Pharmaceutical Industries a Buy on the Dip? (NASDAQ:MNTA)
us.rd.yahoo.com - February 1 at 12:30 AM
News IconStock Vacillating as Volatility Hits a High Point For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Wall Street Beacon (NASDAQ:MNTA)
wsbeacon.com - January 31 at 7:30 PM
247wallst.com logoWhy Analysts Are Chasing Momenta Pharmaceuticals Even Higher - 24/7 Wall St. (NASDAQ:MNTA)
247wallst.com - January 31 at 7:30 PM
News IconWhy Analysts Are Chasing Momenta Pharmaceuticals Even Higher (NASDAQ:MNTA)
feedproxy.google.com - January 31 at 2:37 PM
News IconInvestor Sphere: Keeping an Eye on Levels for Momenta Pharmaceuticals Inc. (MNTA) - Market Point (NASDAQ:MNTA)
mtptnews.com - January 31 at 5:18 AM
News IconTechnical Buzz on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - The Tribune (NASDAQ:MNTA)
lakecitytribune.com - January 29 at 4:44 AM
News IconEarnings Take Center Stage; Analysts Weighing in on Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Aiken Advocate (NASDAQ:MNTA)
aikenadvocate.com - January 26 at 9:47 PM
capitalcube.com logoMomenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : January 24, 2017 (NASDAQ:MNTA)
www.capitalcube.com - January 24 at 7:20 PM
bizjournals.com logoHow These Generic Drugs Stocks are Faring? -- Catalyst Pharma, Sophiris Bio, Momenta Pharma, and Agile Therapeutics (NASDAQ:MNTA)
www.bizjournals.com - January 23 at 10:09 AM
capitalcube.com logoMomenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : January 23, 2017 (NASDAQ:MNTA)
www.capitalcube.com - January 23 at 10:09 AM
News IconChart Indicator Check on Shares of Momenta Pharmaceuticals Inc. (MNTA) - Sherwood Daily (NASDAQ:MNTA)
sherwooddaily.com - January 19 at 5:14 AM
marketnewsvideo.com logoNotable Tuesday Option Activity: AAPL, MNTA, SSTK (NASDAQ:MNTA)
www.marketnewsvideo.com - January 17 at 6:57 PM
News IconTale of the Tape: Technical Recap for Momenta Pharmaceuticals Inc. (MNTA) - Sherwood Daily (NASDAQ:MNTA)
sherwooddaily.com - January 16 at 7:07 PM
News IconMomenta Pharmaceuticals Inc MNTA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:MNTA)
www.bioportfolio.com - January 14 at 6:40 PM

Social

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Where is Momenta Pharmaceuticals' stock going? Where will Momenta Pharmaceuticals' stock price be in 2017?

9 analysts have issued 12-month price targets for Momenta Pharmaceuticals' shares. Their predictions range from $6.00 to $20.00. On average, they expect Momenta Pharmaceuticals' share price to reach $16.78 in the next twelve months.

When will Momenta Pharmaceuticals announce their earnings?

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

What are analysts saying about Momenta Pharmaceuticals stock?

Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:

  • Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)

  • According to Zacks Investment Research, "Momenta received a boost with the FDA approval of Glatopa (a generic version of Copaxone; 20 mg). The drug has captured nearly 40% of the once-daily Copaxone (20 mg) market. Momenta’s efforts to develop its biosimilars pipeline are also impressive. The company has a partnership with Mylan for six of the latter’s biosimilar. Moreover, we are encouraged by the company’s collaboration with Sandoz. The company also has an exclusive research collaboration and worldwide license agreement with CSL Limited for M230. Momenta’s share price has outperformed the Zacks classified Biomedical and Genetics industry in the last twelve months. However, the discontinuation of patient enrolment in a phase II study on necuparanib on the recommendation of an independent Data Safety Monitoring Board following the unfavorable outcome of a planned interim futility analysis is disappointing." (1/16/2017)

Who owns Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.49%), BlackRock, Inc (11.60%), Discovery Capital Management LLC CT (6.48%), Orbimed Advisors LLC (4.28%), Fiera Capital Corp (2.88%) and State Street Corp (2.72%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop, Michael Franken and Richard P Shea.

Who sold Momenta Pharmaceuticals stock? Who is selling Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Dimensional Fund Advisors LP, Oxford Asset Management, Discovery Capital Management LLC CT, Commerzbank Aktiengesellschaft FI, Turner Investments LLC and Envestnet Asset Management Inc.. Company insiders that have sold Momenta Pharmaceuticals stock in the last year include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop and Richard P Shea.

Who bought Momenta Pharmaceuticals stock? Who is buying Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Arrowstreet Capital Limited Partnership, State Street Corp, Renaissance Technologies LLC, Palo Alto Investors LLC, FMR LLC, Guggenheim Capital LLC and Two Sigma Investments LP.

How do I buy Momenta Pharmaceuticals stock?

Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Momenta Pharmaceuticals stock cost?

One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $19.00.

Momenta Pharmaceuticals (NASDAQ:MNTA) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Earnings History Chart

Earnings by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Dividend History Chart

Dividend Payments by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Last Updated on 2/19/2017 by MarketBeat.com Staff